Daclatasvir,Sofosbuvir (Co-Administered) Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: Daclatasvir 60 mg + Sofosbuvir 400 mg

Reference Brands: Daklinza + Sovaldi(Combo)

Category: Hepatitis

Daclatasvir,sofosbuvir (co-administered) is available in Tablet and strengths such as Daclatasvir 60 mg + Sofosbuvir 400 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Daclatasvir,sofosbuvir (co-administered) is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Daclatasvir,sofosbuvir (co-administered) can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Daclatasvir and Sofosbuvir Tablets are an oral, fixed-dose combination used to treat chronic Hepatitis C infection across multiple genotypes. Daclatasvir is an NS5A inhibitor, and Sofosbuvir is an NS5B polymerase inhibitor; together, they provide a highly effective, well-tolerated antiviral regimen. Available as 60 mg Daclatasvir and 400 mg Sofosbuvir tablets, manufactured under EU-GMP and USFDA standards. Ideal for B2B licensing, hospital tenders, and global distribution with full CTD dossiers for fast registration in regulated markets.